Pfizer Faces Antitrust Suit Over Generic Lipitor Delay

Law360, New York (February 6, 2012, 10:38 PM EST) -- A group of health and welfare benefit plans launched a putative class action Monday in New York accusing Pfizer Inc. of filing sham patent applications and of colluding with Ranbaxy Inc. to delay the introduction of generic competitors to cholesterol treatment Lipitor.

The plaintiffs allege that Pfizer and its subsidiaries delayed the date on which generics could have entered the market by fraudulently obtaining a second, duplicative patent from the U.S. Patent and Trademark Office, filing a sham “citizen petition” with the U.S. Food and Drug...
To view the full article, register now.